Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A03272 | Pages: 198 | Charts: 38 | Tables: 91 |
The global narcolepsy drugs market size was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030. Narcolepsy is a chronic sleep disorder that affects the brain’s ability to control sleep-wake cycles. It is characterized by overwhelming daytime drowsiness and sudden attacks of sleep. People with narcolepsy often find it difficult to stay awake for long periods of time and feel very sleepy throughout much of the day.
Get more information on this report : Request Sample Pages
Many individuals with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night. Narcolepsy can affect daily life activities of the sufferers. People with narcolepsy may unwillingly fall asleep in the middle of an activity like driving, eating, or talking. It is usually the first symptom to appear and is often the most troublesome, making it difficult to concentrate on certain activities. Other symptoms include sudden muscle weakness while awake that makes a person go limp or unable to move (cataplexy). Narcolepsy is a lifelong problem and cannot get cured completely but symptoms can partially improve over time with proper medications and lifestyle changes. Increasing stress among individuals consequently leads to a stressful lifestyle and increase in consumption of alcohol, tobacco, and other harmful addictive’s is expected to increase the risk of narcolepsy.
Drug development for narcolepsy treatment has gained incredible momentum the past few years. In addition, governments of countries such as India and South Africa are promoting the production of narcolepsy drug considering its health benefits, which is further expected to boost the narcolepsy drug market growth during the forecast period. Moreover, high disposable income and an increase in awareness about the benefits of narcolepsy drugs are anticipated to boost the growth of the market. However, lower stability, poor sustainability of natural colors derived from narcolepsy drug as compared to synthetic colors, and lack of awareness regarding the diagnosis and treatment availability is predicted to hinder the market growth. There is an increase in the number of programs organized by various organizations mainly to increase the awareness, which is anticipated to provide lucrative opportunities for the narcolepsy drugs market growth.
Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from humans to humans. The COVID-19 pandemic has resulted in nationwide lockdowns, thereby impacting every industry vertical. According to the report of the United Nations Human Rights, the COVID-19 pandemic has threatened all the members of the society. As a result, health care systems are affected, and the effective delivery of medical care and treatment to all patients has become a challenge worldwide. The COVID-19 pandemic is an unprecedented global public health challenge, during the pandemic, global healthcare systems faced many difficult challenges due to severe shortages of hospital beds and medical equipment, patient suffering from COVID-19 having acute respiratory distress syndrome (ARDS) and these patients requires high-level respiratory support to survive.
The social isolation and interruption of daily routines resulting from COVID-19 precautions may impact individuals’ exposure to the light-dark cycle that regulates the circadian system, and thereby exacerbate existing narcolepsy symptoms. Furthermore, the altered bedtime schedules were associated with an increase in excessive daytime sleepiness, which may in turn explain the increase in the use of stimulants. The impact of COVID-19 on narcolepsy drugs was negative during pandemic. The most significant difficulty is that, the patients with narcolepsy may fail to get their prescription due to the restrictions on public transport, home quarantine, and fear of cross-infection in hospitals, resulting in drug discontinuation.
Moreover, due to lack of appropriate treatment available for COVID-19, the manufactures and industries are focusing more on the production of the drugs and equipment’s which are needed for the treatment of COVID-19. Lately, there is not sufficient personal protective equipment (PPE) for hospital workers on the front lines in this terrifying time. All around the world, hospitals are overwhelmed by the volume of patients and the lack of personal protective equipment including face masks, gloves, eye protection and clothing.
The Narcolepsy Drugs Market is segmented into disease type, therapeutic type, and region.
By disease type, the narcolepsy drugs market is categorized into excessive day time sleepiness, cataplexy, and other disease type. The excessive day time sleepiness segment dominates the narcolepsy drugs market. Moreover, drug development for narcolepsy treatment has gained incredible momentum the past few years. Governments of countries such as India and South Africa are promoting the production of narcolepsy drug considering its health benefits, which is further expected to boost the narcolepsy drug market growth.
[DISEASETYPEGRAPH]
Get more information on this report : Request Sample Pages
By therapeutic type, the narcolepsy drugs market is segmented into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type. The sodium oxybate segment dominated the narcolepsy drugs market in 2020 owing to its widespread use in the treatment of narcolepsy symptoms.
[THERAPEUTICTYPEGRAPH]
Get more information on this report : Request Sample Pages
North America spearheaded the narcolepsy drugs market in 2020 and is expected to continue this dominance throughout the forecast period. This is attributed to increase in R&D activities and numerous collaborations between academic and commercial organizations in this region. Increase in acquisition, product launch, and product approval by key players of this market operate in North America turn, fuels growth of the market.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
This report provides comprehensive competitive analysis and profiles of prominent market players such as Arena Pharmaceuticals, Inc., Bioprojet Company, Graymark Healthcare, Inc., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Shionogi Inc., Takeda Pharmaceutical Company Limited, Novartis International AG, and Teva Pharmaceutical Industries Limited.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers, restraints, and opportunity
3.5.2.Drivers
3.5.2.1.Increase in global prevalence of narcolepsy
3.5.2.2.Narcolepsy awareness programs and services
3.5.2.3.Presence of reimbursement policies regarding narcolepsy
3.5.3.Restraints
3.5.3.1.Adverse effects and risks related to narcolepsy drugs
3.5.3.2.Delayed diagnosis or misdiagnosis
3.5.4.Opportunity
3.5.4.1.Untapped markets in the developing countries
3.6.Impact of COVID-19 on the NARCOLEPSY DRUG market
3.6.1.Overview
3.6.2.Impact analysis
CHAPTER 4:NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Daytime extreme sleepiness
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Cataplexia
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Other disease type
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
CHAPTER 5:NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Central nervous system stimulants
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Tricyclic antidepressants
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Sodium oxybate
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Selective serotonin reuptake inhibitor
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Other therapeutic type
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:NARCOLEPSY DRUGS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key opportunities and forecast
6.2.2.Market size and forecast, disease type
6.2.3.Market size and forecast, by therapeutic type
6.2.4.Market size and forecast, by country
6.2.4.1.U.S.
6.2.4.1.1.U.S. market size and forecast, by disease type
6.2.4.1.2.U.S. market size and forecast, by therapeutic type
6.2.4.2.Canada
6.2.4.2.1.Canada market size and forecast, by disease type
6.2.4.2.2.Canada market size and forecast, by therapeutic type
6.2.4.3.Mexico
6.2.4.3.1.Mexico market size and forecast, by disease type
6.2.4.3.2.Mexico market size and forecast, by therapeutic type
6.3.Europe
6.3.1.Key opportunities and forecast
6.3.2.Market size and forecast, by disease type
6.3.3.Market size and forecast, by therapeutic type
6.3.4.Market size and forecast, by country
6.3.4.1.Germany
6.3.4.1.1.Germany market size and forecast, by disease type
6.3.4.1.2.Germany market size and forecast, by therapeutic type
6.3.4.2.France
6.3.4.2.1.France market size and forecast, by disease type
6.3.4.2.2.France market size and forecast, by therapeutic type
6.3.4.3.UK
6.3.4.3.1.UK market size and forecast, by disease type
6.3.4.3.2.UK market size and forecast, by therapeutic type
6.3.4.4.Italy
6.3.4.4.1.Italy market size and forecast, by disease type
6.3.4.4.2.Italy market size and forecast, by therapeutic type
6.3.4.5.Spain
6.3.4.5.1.Spain market size and forecast, by disease type
6.3.4.5.2.Spain market size and forecast, by therapeutic type
6.3.4.6.Rest of Europe
6.3.4.6.1.Rest of Europe market size and forecast, by disease type
6.3.4.6.2.Rest of Europe market size and forecast, by therapeutic type
6.4.Asia-Pacific
6.4.1.Key opportunities and forecast
6.4.2.Market size and forecast, by disease type
6.4.3.Market size and forecast, therapeutic type
6.4.4.Market size and forecast, by country
6.4.4.1.Japan
6.4.4.1.1.Japan market size and forecast, by disease type
6.4.4.1.2.Japan market size and forecast, by therapeutic type
6.4.4.2.China
6.4.4.2.1.China market size and forecast, by disease type
6.4.4.2.2.China market size and forecast, by therapeutic type
6.4.4.3.Australia
6.4.4.3.1.Australia market size and forecast, by disease type
6.4.4.3.2.Australia market size and forecast, by therapeutic type
6.4.4.4.India
6.4.4.4.1.India market size and forecast, by disease type
6.4.4.4.2.India market size and forecast, by therapeutic type
6.4.4.5.South Korea
6.4.4.5.1.South Korea market size and forecast, by disease type
6.4.4.5.2.South Korea market size and forecast, by therapeutic type
6.4.4.6.Rest of Asia-Pacific
6.4.4.6.1.Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.6.2.Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5.LAMEA
6.5.1.Key opportunities and forecast
6.5.2.Market size and forecast, by disease type
6.5.3.Market size and forecast, by therapeutic type
6.5.4.Market size and forecast, by country
6.5.4.1.Brazil
6.5.4.1.1.Brazil market size and forecast, by disease type
6.5.4.1.2.Brazil market size and forecast, by therapeutic type
6.5.4.2.Saudi Arabia
6.5.4.2.1.Saudi Arabia market size and forecast, by disease type
6.5.4.2.2.Saudi Arabia market size and forecast, by therapeutic type
6.5.4.3.South Africa
6.5.4.3.1.South Africa market size and forecast, by disease type
6.5.4.3.2.South Africa market size and forecast, by therapeutic
6.5.4.4.Rest of LAMEA
6.5.4.4.1.Rest of LAMEA market size and forecast, by disease
6.5.4.4.2.Rest of LAMEA market size and forecast, by therapeutics
CHAPTER 7:COMPANY PROFILES153
7.1.Arena Pharmaceuticals, Inc.
7.1.1.Company overview
7.1.2.Operating business segments
7.1.3.Product portfolio
7.1.4.Business performance
7.2.BIOPROJET COMPANY
7.2.1.Company overview
7.2.2.Operating business segments
7.2.3.Product portfolio
7.3.GRAYMARK HEALTHCARE, INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.4.Hikma Pharmaceuticals Plc
7.4.1.Company overview
7.4.2.Operating business segments
7.4.3.Product portfolio
7.4.4.Business performance
7.4.5.Key strategic moves and developments
7.5.JAZZ PHARMACEUTICALS PLC
7.5.1.Company overview
7.5.2.Operating business segments
7.5.3.Product portfolio
7.5.4.Business performance
7.5.5.Key strategic moves and developments
7.6.LIGAND PHARMACEUTICALS, INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.Shionogi Inc.
7.7.1.Company overview
7.7.2.Operating business segments
7.7.3.Product portfolio
7.7.4.Business performance
7.8.Takeda Pharmaceutical Company Limited
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.NOVARTIS INTERNATIONAL AG
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1.Company overvie
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL NARCOLEPSY DRUGS MARKET REVENUE, BY DISEASE, 2020–2030 ($MILLION)
TABLE 02.NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2020–2030 ($MILLION)
TABLE 05.GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 06.NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2020–2030 ($MILLION)
TABLE 07.NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020–2030 ($MILLION)
TABLE 08.SODIUM OXYBATE FOR NARCOLEPSY DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 09.NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2020–2030 ($MILLION)
TABLE 10.NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2020–2030 ($MILLION)
TABLE 11.NARCOLEPSY DRUGS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA NARCOLEPSY DRUG MARKET, THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 15.U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 16.U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 17.CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 18.CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 19.MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 20.MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 21.EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 22.EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 23.EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 24.GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 25.GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 26.FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 27.FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 28.UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 29.UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 30.ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 31.ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 32.SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 33.SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 34.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 35.REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 36.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 37.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 38.ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 39.JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 40.JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 41.CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 42.CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 43.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 45.INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 46.INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 47.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 48.SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 50.REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 51.LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 52.LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 53.LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 55.BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION
TABLE 56.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 57.SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020–2030 ($MILLION)
TABLE 58.SOUTH AFRICA NARCOLEPSY DRUG MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 59.SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC, 2020–2030 ($MILLION)
TABLE 60.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 61.REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 62.ARENA PHARMA: COMPANY SNAPSHOT
TABLE 63.ARENA PHARMA: OPERATING SEGMENTS
TABLE 64.ARENA PHARMA: PRODUCT PORTFOLIO
TABLE 65.BIOPROJET: COMPANY SNAPSHOT
TABLE 66.BIOPROJET: OPERATING SEGMENTS
TABLE 67.BIOPROJET: PRODUCT PORTFOLIO
TABLE 68.GRAYMARK HEALTHCARE: SNAPSHOT
TABLE 69.GRAYMARK HEALTHCARE: OPERATING SEGMENTS
TABLE 70.GRAYMARK HEALTHCARE: PRODUCT PORTFOLIO
TABLE 71.HIKMA: COMPANY SNAPSHOT
TABLE 72.HIKMA: OPERATING SEGMENTs
TABLE 73.HIKMA: PRODUCT PORTFOLIO
TABLE 74.JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 75.JAZZ PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 76.JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 77.LIGAND PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 78.LIGAND PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 79.LIGAND PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 80.SHIONOGI: COMPANY SNAPSHOT
TABLE 81.SHIONOGI: OPERATING SEGMENTS
TABLE 82.SHIONOGI: PRODUCT PORTFOLIO
TABLE 83.TAKEDA: COMPANY SNAPSHOT
TABLE 84.TAKEDA: OPERATING SEGMENTS
TABLE 85.TAKEDA: PRODUCT PORTFOLIO
TABLE 86.NOVARTIS: COMPANY SNAPSHOT
TABLE 87.NOVARTIS: OPERATING SEGMENTS
TABLE 88.NOVARTIS: PRODUCT PORTFOLIO
TABLE 89.TEVA: COMPANY SNAPSHOT
TABLE 90.TEVA: OPERATING SEGMENTS
TABLE 91.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.NARCOLEPSY DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW THREAT OF NEW ENTRANTS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITY
FIGURE 13.NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY 2020 & 2030 (%)
FIGURE 17.NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2020 & 2030 (%)92
FIGURE 21.ARENA PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.HIKMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.HIKMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24.HIKMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25.JAZZ PHARMACEUTICALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.JAZZ PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.LIGAND PHARMACEUTICALS: REVENUE, 2018–2020 ($MILLION)
FIGURE 28.LIGAND PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.SHIONOGI: REVENUE, 2018–2020 ($MILLION)
FIGURE 30.SHIONOGI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SHIONOGI: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 32.TAKEDA: REVENUE, 2018–2020 ($MILLION)
FIGURE 33.TAKEDA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 35.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 37.TEVA: REVENUE, 2018–2020 ($MILLION)
FIGURE 38.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)